Skip to main content
CTMX logo

CTMX

CytomX Therapeutics, Inc.

$2.04

0.73%

Trade Ideas Performance

Latest Closed Trade Idea

$2.04

0.73%
Loading...
We are loading your data. Please wait a moment.

Sentiment

News

29

Social

3

About

Events of CytomX Therapeutics, Inc. (CTMX)

Over the past six months, CytomX Therapeutics' stock price declined approximately 45.6% to 45.79%. Key events included the FDA Fast Track Designation for Varsetatug masetecan in late August 2026, which was a positive development. However, the Q2 and Q3 2026 earnings reports showed substantial year-over-year revenue decreases and adjusted losses, missing analysts' consensus estimates, which negatively impacted investor sentiment. The company expanded its collaboration with Regeneron Pharmaceuticals, receiving $37 million for two additional programs with potential milestones reaching approximately $4 billion, extending its cash runway into the second half of 2028. Analyst price targets vary, with some maintaining 'Outperform' ratings and raising targets, while others highlight risks such as financing-related dilution and declining collaboration revenue. Investor uncertainty has also been created by the absence of near-term, definitive pivotal clinical trial data readouts for key pipeline assets.

FAQ

Related Assets

Price action provided by Massive. Fundamentals, news and corporate events provided by FactSet. NLP support provided by Perplexity & Gemini. All data is provided for informational purposes only.

Make every trade make sense.

Sign up free. No card required. Three trade ideas a day, the AI analyst, the community - on us.

Get started for FREE (opens in new tab)
Edge Hound mobile app preview on iPhone

Join us and trade with people
who think like you.

The Edge Hound Discord is where serious self-directed investors talk strategy, share setups, and learn from each other. Free to join with any plan - including Free.

Free to join with any plan - including Free.

Join our Discord community (opens in new tab)